Besides the significant weight loss effect demonstrated by the GLORY-1 study (NCT05607680), mazdutide has been shown to counteract the hyperglycemia induced by GCGR activation by adequately balancing the effects of GLP-1R and GCGR activation, overall reducing HbA1c levels and fasting glucose [102,103]. This evidence concerns the gene GLP1R and Hyperglycemia.